Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Company Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect® and Teverelix® Programs and a Strengthened Financial Position Supporting Continued Pipeline Execution and Expansion PHILADELPHIA, PA / ACCESS …